Cargando…
Tigecycline as a Second-Line Agent for Legionnaires’ Disease in Severely Ill Patients
Treatment of Legionnaires’ disease in severely ill or immunosuppressed patients presents a clinical challenge. Tigecycline (TG) achieves high concentrations intracellularly and has been shown to be effective against L. pneumophila in animal and cell models. We report our experience using TG as secon...
Autores principales: | Slawek, Deepika, Altshuler, Diana, Dubrovskaya, Yanina, Louie, Eddie |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5632526/ https://www.ncbi.nlm.nih.gov/pubmed/29026871 http://dx.doi.org/10.1093/ofid/ofx184 |
Ejemplares similares
-
Invasive Nontyphoidal Salmonella Infection in a Patient with Early-Stage Chronic Lymphocytic Leukemia
por: Slawek, Deepika, et al.
Publicado: (2017) -
Outcomes of Cytomegalovirus Viremia Treatment in Critically Ill Patients With COVID-19 Infection
por: Schoninger, Scott, et al.
Publicado: (2022) -
Successful Treatment of Legionnaires’ Disease with Tigecycline in an Immunocompromised Man with a Legion of Antibiotic Allergies
por: Arget, Michael, et al.
Publicado: (2019) -
Stability studies with tigecycline in bacterial growth medium and impact of stabilizing agents
por: Amann, Lisa F., et al.
Publicado: (2020) -
A Legionnaires’ Disease Cluster in a Private Building in Italy
por: Ricci, Maria Luisa, et al.
Publicado: (2021)